510(k) Report

PMA · Approved

Approved

Elecsys Total Psa Immunoassay and Total Psa Calset

P990056PMAApproved Nov 22, 2000415-day reviewClass III

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Roche Diagnostics Corp. · MTF Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer

Approved on Nov 22, 2000 through premarket approval, which rests on the device’s own clinical evidence after a 415-day review.

Decided
Nov 22, 2000
Review
415 days
Class
Class III
Product code
MTF
Recalls
None

PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.

P990056 has 43 supplements since 2002: changes to the approved device, its labelling or its manufacturing, each approved separately.

PMA supplements approved per year

2002: 12006: 32007: 12008: 32009: 12011: 42012: 42014: 22015: 12016: 22017: 42018: 52019: 22020: 12021: 12023: 22024: 32025: 12026: 2
2002high 5 (2018) · low 0 (2003)2026
View FIG. 1 as a table
YearSupplements approved
20021
20063
20071
20083
20091
20114
20124
20142
20151
20162
20174
20185
20192
20201
20211
20232
20243
20251
20262
FIG. 1 — Supplements to P990056, 2002–2026Source: FDA PMA database

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MTF? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

Does it have a predicate?

PMA decisions do not claim a predicate device.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All MTF devices

MTF Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · MTF

8in 2025

2007: 52008: 92009: 72010: 102011: 262012: 192013: 162014: 142015: 82016: 62017: 122018: 102019: 82020: 142021: 62022: 52023: 102024: 42025: 82026 (partial year): 9
2007high 26 (2011) · low 4 (2024)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MTF

Too few MTF 510(k)s in any year since 2007 to give a median.

Recalls per year · MTF

1in 2024

2008: 12012: 12015: 12016: 22024: 1
2007high 2 (2016) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MTF

65in 2025

2007: 12008: 42009: 32010: 52011: 102012: 172013: 892014: 122015: 172016: 162017: 392018: 302019: 212020: 142021: 462022: 452023: 292024: 312025: 65
2007high 89 (2013) · low 1 (2007)2025

MAUDE reports naming product code MTF, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20075—01
20089—14
20097—03
201010—05
201126—010
201219—117
201316—089
201414—012
20158—117
20166—216
201712—039
201810—030
20198—021
202014—014
20216—046
20225—045
202310—029
20244—131
20258—065
20269—0—
Cite this page

510(k) Report. “P990056: Elecsys Total Psa Immunoassay and Total Psa Calset.” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/P990056

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Page last updated Nov 3, 2026